Ocugen Sets October Record Date as Investors Weigh Share Authorization Against 2027 Clinical Readout

Ocugen has pushed its extraordinary shareholder meeting back to 22 December 2026, with a 30 October 2026 record date now fixed for determining who is entitled to vote. The sole item on the agenda is a proposal to raise the number of authorized common shares by 250,000,000, according to a regulatory filing. The postponement — originally scheduled for 14 October — means the company will first settle the question of which shareholders count before the vote itself takes place.

The distinction between authorization and issuance sits at the heart of the matter. Approval would expand the permitted share capital ceiling; it would not constitute a completed stock sale, nor would it deliver an immediate cash inflow. Just as importantly, the size of the requested authorization says nothing about how many additional shares might eventually be issued, or on what terms.

A Pipeline Measured in Filing Targets

Separately, Ocugen used an investor presentation — delivered roughly two weeks ago — to sketch its ophthalmology gene therapy roadmap. The company is targeting BLA submissions for three programs between 2027 and 2028, and it pointed to first summary results from the Phase 3 liMeliGhT trial of OCU400 in the first quarter of 2027.

Those are objectives, not achievements. No submission has been filed and no results have been reported. For anyone assessing the equity, the gap between an intended procedural step and its eventual outcome is the relevant unit of analysis — a plan is not an application, and an application is not an approval.

Roots Deal: A Ceiling, Not a Floor

A commercial framework took shape around two weeks ago through an exclusive agreement with Roots Pharmaceutical Company covering OCU400 for retinitis pigmentosa in selected countries across the Middle East and North Africa. Ocugen is to manufacture and supply the product under a supplementary supply arrangement.

The terms include an initial license fee and possible upfront development payments of up to $4 million, plus sales-dependent milestones of up to $255 million and royalties of 22% on net sales. Those headline figures describe maximum possible amounts, not assured total revenue. The structure matters more than the sum: early payments on one side, revenue-tied components on the other. The sales-linked pieces bind the contract's value to commercial performance that has yet to materialize, and they should not be mentally pooled into a financing cushion already in hand.

Three Questions, Three Different Clocks

What emerges is a company whose story runs on separate tracks that are easily conflated. The shareholder vote addresses financial headroom. The liMeliGhT readout addresses whether the development program holds up. The Roots contract addresses the conditions under which future payments could arrive. None of these resolves the others.

A capital authorization could enable later measures; contractual possibilities could turn into revenue; development targets could turn into filings. The sequence is what counts, not the largest number on the page. Investors who keep the layers apart are valuing a development path with clearly distinct conditions — not a finished success story.